William Looney

Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry

Pharm Exec speaks with Spanish-born Belén Garijo, CEO of Merck KGaA, Darmstadt, Germany’s healthcare business, who shares her steady-eyed approach in transforming a traditional pharma unit focused on small molecules for chronic disease to a high-tech specialty producer of immunotherapy drugs for rare cancers.

In a continent marked by stark differences in governance, growth and market potential, the best bets must be pursued off script.

Pharm Exec sits down with veteran journalist Paula Apsell, the driving force behind the long-running PBS science series NOVA. Apsell offers straightforward advice to the biopharma industry: make your business a business of inspiration, where the return is measured in passion-and the sheer, simple pleasure of finding things out.

Despite Big Pharma's success in translating discovery research into products with proven clinical value, the industry continues to struggle in positioning medical research to the public as a distinctive force for good.

The influx of treatment breakthroughs and expanding science has not silenced the debate over the productivity of biopharma's R&D model, and the looming challenges for R&D decision-makers.

Founder and CEO, Bloodbuy

Vice President and Head, Innovation Center, Global Health and Value, Pfizer Inc.

Pharm Exec convenes an expert Roundtable to discuss one of the hottest topics in big data today-how to make that data relevant to payers, regulators and the patient through reliance on real-world evidence in driving better health outcomes.

President, US Pharmaceuticals, Bayer

Highlighting the seven key trends in global pharma that drove discussion at this year's CPhI Worldwide event in Spain.

Co-Founders, twoXAR

Pharm Exec sits down with UBC President Patrick Lindsay to provide some real-world context around our 2016 feature profile of sixteen Emerging Leaders in biopharma.

Pharm Exec sits down with Anthony Marucci, co-founder and CEO of Celldex, a stealth player in the immunotherapy field.

Pharm Exec and inVentiv Health convened a roundtable discussion at the 2016 ASCO meeting to review the use of patient-reported outcomes (PRO) in the clinical trial and commercialization space.

Big pharma has become increasingly vulnerable to larger geopolitical and macroeconomic risks-a realization that has slowly creeped into their business planning.

With our annual Industry Audit marking its 15th year, we decided to compare 2002 approaches in boosting shareholder value to those of today. The fall in one particular performance metric is telling.

Pharm Exec sits down with AmerisourceBergen supply chain leader Peyton Howell to discuss the latest trends in pharmaceutical distribution, including company efforts to boost efficiency, reliability, and enhance its groundbreaking partnership with Walgreens Boots Alliance.

Pharm Exec’s 16th annual listing of the top biopharma players may look placid on the surface, but, upon deeper inspection, does point to important transitions taking place in the larger business model.

Pharm Exec convenes a roundtable discussion with several company chief information officers (CIOs) and IMS Health to explore ways to turn the vast reams of data now being generated in the transactional tsunami of modern healthcare into truly meaningful insights for its users.

Pharm Exec sits down with Habib Dable, a 22-year veteran of Bayer, to discuss his few first months at the helm of the company’s US pharma operations, where he is leading Bayer’s repositioning as a drug innovator and advancing its “all-in” approach to product partnering.

Amid today's growing constituency of cancer survivors, oncology is testing the historic divide in medicine between what’s science and what’s social.

Pharm Exec explores the power of workplace aesthetic on the intangibles of culture, morale-and corporate mission-in a visit to one big Pharma's unique US headquarters.

A new educational and potential prognosis tool for the treatment of multiple sclerosis shows how an accessible, easy-to-see visualization of disease state can serve as the threshold for fresh clinical insight-all geared to the individual patient.

A conversation with GlaxoSmithKline's US Pharmaceuticals head Jack Bailey.

The Boston biotech cluster proved an ideal setting for Pharm Exec's recent annual Editorial Advisory Board meeting, with the prevailing message that even the best environments for innovation require constant nurturing.

William Looney speaks with DIA's Global Chief Executive to see how the organization is repositioning itself as the go-to place for the independent insights in a business with no boundaries.

How the DIA, a key industry NGO, is repositioning itself as the go-to place for the independent knowledge-driven insights that drive decisions in a business with no boundaries. One world. One table. Open seating.

The challenges facing the ad industry and big Pharma are remarkably similar-a point driven home by four distinct themes at this year's 4A's Transformation conference illustrate.

With the emerging industry commitment to publicly disclose research and clinical trial results, two pivotal issues come to mind - and serve as a reminder to companies that true transparency depends on the truthfulness of the evidence that binds it.